已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

医学 肝细胞癌 核医学 新辅助治疗 肝切除术 实体瘤疗效评价标准 放射科 进行性疾病 内科学 化疗 癌症 外科 乳腺癌 切除术
作者
Qiang Li,Xiaolan Wang,Deju Li,Yulong Liu,Kangshou Liu,Junjie Liang,Jian Sun,Quan Jiang,Jiexing Li,Zhilong Liu,Jian Gong,Leyang Xiang,Zhidong Jia,Zhiwei Chen,Mingrong Cao,Yuchuan Jiang
出处
期刊:Journal of Visualized Experiments [MyJOVE]
卷期号: (207) 被引量:2
标识
DOI:10.3791/66407
摘要

This study showcases a comprehensive treatment protocol for high-risk hepatocellular carcinoma (HCC) patients, focusing on the combined use of Y-90 transarterial radioembolization (TARE) and Programmed Cell Death-1 (PD-1) inhibitors as neoadjuvant therapy. Highlighted through a case report, it offers a step-by-step reference for similar therapeutic interventions. A retrospective analysis was conducted on a patient who underwent hepatectomy following Y-90 TARE and PD-1 inhibitor treatment. Key demographic and clinical details were recorded at admission to guide therapy selection. Y-90 TARE suitability and dosage calculation were based on Technetium-99m (Tc-99m) macroaggregated albumin (MAA) perfusion mapping tests. Lesion coverage by Y-90 microspheres was confirmed through single photon emission computed tomography/computed tomography (SPECT/CT) fusion imaging, and adverse reactions and follow-up outcomes were meticulously documented. The patient, with a 7.2 cm HCC in the right hepatic lobe (T1bN0M0, BCLC A, CNLC Ib) and an initial alpha-fetoprotein (AFP) level of 66,840 ng/mL, opted for Y-90 TARE due to high recurrence risk and initial surgery refusal. The therapy's parameters, including the lung shunting fraction (LSF) and non-tumor ratio (TNR), were within therapeutic limits. A total of 1.36 GBq Y-90 was administered. At 1 month post-therapy, the tumor shrank to 6 cm with partial necrosis, and AFP levels dropped to 21,155 ng/mL, remaining stable for 3 months. After 3 months, PD-1 inhibitor treatment led to further tumor reduction to 4 cm and AFP decrease to 1.84 ng/mL. The patient then underwent hepatectomy; histopathology confirmed complete tumor necrosis. At 12 months post-surgery, no tumor recurrence or metastasis was observed in follow-up sessions. This protocol demonstrates the effective combination of Y-90 TARE and PD-1 inhibitor as a bridging strategy to surgery for HCC patients at high recurrence risk, providing a practical guide for implementing this approach.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Lxxx发布了新的文献求助10
2秒前
snowman完成签到,获得积分10
3秒前
3秒前
眯眯眼的山柳完成签到 ,获得积分10
4秒前
卿亦佳人发布了新的文献求助10
5秒前
dd完成签到 ,获得积分10
5秒前
chenjunyong17完成签到,获得积分10
6秒前
snowman发布了新的文献求助10
7秒前
slz发布了新的文献求助10
9秒前
欢呼的访文完成签到,获得积分10
9秒前
研友_VZG7GZ应助买不起A7采纳,获得10
11秒前
11秒前
Yas完成签到,获得积分10
12秒前
胡明轩完成签到 ,获得积分10
12秒前
13秒前
哈基伟完成签到,获得积分10
14秒前
舍曲林完成签到,获得积分10
14秒前
15秒前
痴情的不惜完成签到,获得积分10
15秒前
15秒前
南风发布了新的文献求助10
16秒前
16秒前
胡凯发布了新的文献求助10
17秒前
斯文败类应助小雪采纳,获得10
17秒前
YuJiao发布了新的文献求助10
19秒前
SCINEXUS完成签到,获得积分0
19秒前
Rowena发布了新的文献求助10
19秒前
含蓄衣完成签到,获得积分10
19秒前
chenjunyong17发布了新的文献求助10
20秒前
20秒前
米龙完成签到,获得积分10
20秒前
吴大王完成签到,获得积分10
20秒前
佐伊完成签到 ,获得积分10
20秒前
开朗满天完成签到 ,获得积分10
21秒前
元气弹完成签到 ,获得积分10
21秒前
21秒前
mdwm完成签到 ,获得积分10
21秒前
梦回唐朝完成签到 ,获得积分10
22秒前
哭泣含卉发布了新的文献求助10
22秒前
杨梅想早点毕业完成签到 ,获得积分10
23秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Principles of town planning: translating concepts to applications 1000
Management and the Arts 510
Matrix Methods in Data Mining and Pattern Recognition Second Edition 510
The role of consumer psychology in the marketing strategies of pop mart in Thailand 500
核安全综合知识2024版 500
Photothermal Science and Techniques 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 内科学 物理 复合材料 催化作用 细胞生物学 无机化学 光电子学 物理化学 电极 基因
热门帖子
关注 科研通微信公众号,转发送积分 7720206
求助须知:如何正确求助?哪些是违规求助? 9274031
关于积分的说明 20100033
捐赠科研通 7296550
什么是DOI,文献DOI怎么找? 3300072
关于科研通互助平台的介绍 2453870
邀请新用户注册赠送积分活动 2307527